New hope for advanced cervical cancer: Triple-Drug combo trial launches
NCT ID NCT07177716
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This clinical trial is testing whether a combination of two immunotherapy drugs (LB1410 and LB4330) plus a targeted therapy (lenvatinib) can shrink tumors or slow disease progression in people with advanced cervical cancer that has returned or spread. The study will compare this new combo against standard chemotherapy chosen by the doctor. About 120 participants will be enrolled, and the main goals are to see how many patients respond and how long the response lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LB1410 (an immunotherapy drug) plus lenvatinib (a targeted therapy), with or without LB4330 (another immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with advanced cervical cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-to-mid stage trial with only 120 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and there is no guarantee it will work better than existing chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact